New Findings on Inflammatory Bowel Disease from Celltrion Inc Summarized (Comparable Immune Function Inhibition by the Infliximab Biosimilar CT-P13: Implications for Treatment of Inflammatory Bowel Disease)
By a News Reporter-Staff News Editor at Drug Week Current study results on Digestive System Diseases and Conditions - Inflammatory Bowel Disease have been published. According to news reporting out of Incheon, South Korea, by NewsRx editors, research stated, "CT-P13 is the first biosimilar monoclonal antibody to infliximab, and was recently approved in the European Union, Japan, Korea, and USA for all six indications of infliximab. However, studies directly assessing the biologic activity of CT-P13 versus inflximab in the context of inflammatory bowel disease [IBD] are still scanty."
Our news journalists obtained a quote from the research from Celltrion Inc, "In the present study, we aimed to compare the biological activities of CT-P13 and infliximab with specific focus on intestinal cells so as to gain insight into the potential biosimilarity of these two agents for treatment of IBD. CT-P13 and infliximab were investigated and compared by in vitro experiments for their neutralisation ability of soluble tumor necrosis factor alpha [sTNFa] and membrane-bound tumor necrosis factor alpha [mTNFa], suppression of cytokine release by reverse signalling, induction of regulatory macrophages and wound healing, and antibody-dependent cell cytotoxicity [ADCC]. CT-P13 showed similar biological activities to infliximab as gauged by neutralisation of soluble TNFa, as well as blockade of apoptosis and suppression of pro-inflammatory cytokines in intestinal Caco-2 cells. Infliximab and CT-P13 equally induced apoptosis and outside-to-inside signals through transmembrane TNFa [tmTNFa]. Moreover, regulatory macrophage induction and ensuing wound healing were similarly exerted by CT-P13 and infliximab. However, neither CT-P13 nor infliximab exerted any significant ADCC of ex vivo-stimulated peripheral blood monocytes or lamina propria mononuclear cells from IBD patients."
According to the news editors, the research concluded: "These findings indicate that CT-P13 and infliximab exert highly similar biological activities in intestinal cells, and further support a mechanistic comparability of these two drugs in the treatment of IBD."
For more information on this research see: Comparable Immune Function Inhibition by the Infliximab Biosimilar CT-P13: Implications for Treatment of Inflammatory Bowel Disease. Journal of Crohn's & Colitis, 2017;11(5):593-602. (Elsevier - www.elsevier.com; Journal of Crohn's & Colitis - www.journals.elsevier.com/journal-of-crohns-and-colitis/)
Our news journalists report that additional information may be obtained by contacting K.J. Lim, R&D Division, Celltrion Inc, Incheon, South Korea. Additional authors for this research include S.J. Lee, S. Kim, S.Y. Lee, M.S. Lee, Y.A. Park, E.J. Choi, E.B. Lee, H.K. Jun, J.M. Cho, S. Lee, K.S. Kwon, B.P. Lim, M.S. Jeon, E.C. Shin, Y.S. Choi, E. Fudim, O. Picard, M. Yavzori, S. Ben-Horin and S.J Chang (see also Digestive System Diseases and Conditions - Inflammatory Bowel Disease).
Keywords for this news article include: Asia, Antirheumatics, Biotechnology, Pharmaceuticals, Incheon, Infliximab, South Korea, Gastroenteritis, Immunologic Agents, Drugs and Therapies, Monoclonal Antibodies, Inflammatory Bowel Disease, Bowel Diseases and Conditions, Tumor Necrosis Factor (TNF) Inhibitors, Digestive System Diseases and Conditions.
Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2017, NewsRx LLC